The cost-effectiveness of tiotropium for the treatment of chronic obstructive pulmonary disease (COPD): the importance of the comparator

European Journal of Health Economics

Volumn 13, Issue 4, 2012, Pages 379-380

  Neyt, Mattias ^a   Van Den Bruel, Ann ^b  

^a BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FORMOTEROL; INDACATEROL; SALMETEROL; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; ECONOMIC EVALUATION; HOSPITALIZATION; HUMAN; MORTALITY; NOTE; PHARMACOECONOMICS; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT;

BRONCHODILATOR AGENTS; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 84865595712     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-012-0392-9     Document Type: Note

References (8)

1. Zaniolo, O., Iannazzo, S., Pradelli, L., Miravitlles, M.: Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. Eur J Health Econ 13(1), 71-80 (2012). doi:10.1007/s10198-010-0285-8)
2. Neyt, M., Van Brabandt, H.: The importance of the comparator in economic evaluations: Working on the efficiency frontier. PharmacoEconomics 29(11), 913-916 (2011). doi:10.2165/11595260-000000000-00000)
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2011). http://www.goldcopd.org/
4. Neyt, M., Van den Bruel, A., Gailly, J., Thiry, N., Devriese, S.: Tiotropium in the treatment of chronic obstructive pulmonary disease: Health technology assessment. In: Health Technology Assessment. KCE reports 108C. Belgian Health Care Knowledge Centre (KCE), Brussels (2009)
5. Van den Bruel, A., Gailly, J., Neyt, M.: Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: Results of a meta-analysis. BMC Pulm Med 10, 50 (2010). doi: 10.1186/1471-2466-10-50)
6. Brusasco, V., Hodder, R., Miravitlles, M., Korducki, L., Towse, L., Kesten, S.: Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58(5), 399-404 (2003) (Pubitemid 36560942)
7. Briggs Jr, D.D., Covelli, H., Lapidus, R., Bhattycharya, S., Kesten, S., Cassino, C.: Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm. Pharmacol. Ther. 18(6), 397-404 (2005) (Pubitemid 41354265)
8. National Institute for Health and Disability Insurance: Individual revision of the pharmaceutical product Spiriva. Rijksinstituut voor Ziekte-en Invaliditeitsverzekering (RIZIV), Brussels (2007)